A New York pharmaceutical company, TGV-Laboratories, has developed a groundbreaking drug that shows promise in treating a wide variety of antibiotic-resistant fungal and bacterial infections.

The research duo of Victor and George Tetz, the scientific core of TGV-Laboratories, said human trials indicate their discovery, called Mul-1867, has the potential for being developed into a new generation of infection-fighting drugs that can treat all infections caused by antibiotic resistant microorganisms, from ventilator-associated and fungal pneumonia to wound infections and gangrene.

The problem of antibiotic resistance has been widely discussed in recent years, with reports from the Review on Antimicrobial Resistance estimating that medicine-resistant infections will take more lives annually than cancer does by 2050.

“According to this important scientific journal, deaths caused by drug resistance will rise from 700,000 in 2015 to an estimated 10 million per year in 2050,” said Dr. George Tetz, scientific core of TGV-Laboratories. “Some respected researchers are warning of an imminent post-antibiotic era, or ‘antibiotic apocalypse.’ We believe our research has unlocked a key for fighting some of these most dangerous bacterial and fungal pathogens that have grown resistant to drugs currently on the market. We are eager to expand human trials of our discovery, which in studies and tests to date have shown it to be highly effective and without side effects.”

TGVs subsidiary, TGV-Inhalonix, recently filed an application with the Food and Drug Administration seeking Orphan Drug Status for Mul-1867 to be tested on cystic fibrosis patients with life-threatening antimicrobial-resistant pulmonary infections.

But TGV says it will also continue to study the drug’s broader potential as a next-generation antibiotic.

TGV recently presented study results on Mul-1867 at America’s largest microbiology conferences – ASM-2015 and ICAAC-2015. The first article about the novel compound was recently published in the Antimicrobial Resistance and Infection Control Journal (http://www.aricjournal.com/content/4/1/45 or http://www.ncbi.nlm.nih.gov/pubmed/26550474).

“Taken together, our data suggested that Mul-1867 is a promising novel antimicrobial agent that has potent broad-spectrum antibacterial and antifungal activity against clinically important microorganisms, including multi-resistant ones that today are practically incurable,” said Prof. Dr. Michael Cynamon, an infectious disease specialist at the Veterans Affairs Medical Center in Syracuse, New York, and a member of TGV’s advisory board.

Mul-1867 and some other novel antibacterial and antifungal drug candidates that are in TGV-Laboratories pipeline were discovered as the result of years of research by Victor and George Tetz using a new concept they developed called Pangenome (http://www.ncbi.nlm.nih.gov/pubmed/15990697). This concept acts like a guide that helps mark new therapeutic targets for drugs. The Institute of Human Microbiology assisted TGV with Mul-1867’s discovery.

For more information about Victor and George Tetz and TGV-Inhalonix, please contact Jeri Clausing MVG at 505-221-3108, jeri(at)mvgmain.com; or Denis Senkov, denis(at)mvgmain.com

TGV-Laboratories Group of Companies. (http://tgv-labs.com) is a research-based pharmaceutical company headquartered in New York that provides a broad range of innovative products to treat currently untreatable infectious, autoimmune and neurodegenerative diseases. TGV operates under two divisions: the Division of Drug Discovery & Development and the Division of Medical & Industrial Microbiology.